155 related articles for article (PubMed ID: 2492205)
1. Comparative study of plasminogen activators in cancers and normal mucosae of human urinary bladder.
Hasui Y; Suzumiya J; Marutsuka K; Sumiyoshi A; Hashida S; Ishikawa E
Cancer Res; 1989 Feb; 49(4):1067-70. PubMed ID: 2492205
[TBL] [Abstract][Full Text] [Related]
2. Plasminogen activator content of human tumor and adjacent normal tissue measured with fibrin and non-fibrin assays.
Camiolo SM; Greco WR
Cancer Res; 1986 Apr; 46(4 Pt 1):1788-94. PubMed ID: 3081257
[TBL] [Abstract][Full Text] [Related]
3. Components of the plasminogen activation system in uveal melanoma--a clinico-pathological study.
De Vries TJ; Mooy CM; Van Balken MR; Luyten GP; Quax PH; Verspaget HW; Weidle UH; Ruiter DJ; Van Muijen GN
J Pathol; 1995 Jan; 175(1):59-67. PubMed ID: 7891228
[TBL] [Abstract][Full Text] [Related]
4. Plasminogen activators in human nasal polyps and mucosa.
Larsen K; de Maat MP; Jespersen J
Rhinology; 1997 Dec; 35(4):175-7. PubMed ID: 9532638
[TBL] [Abstract][Full Text] [Related]
5. Urokinase-type plasminogen activator in colorectal cancer: relationship with clinicopathological features and patient outcome.
Skelly MM; Troy A; Duffy MJ; Mulcahy HE; Duggan C; Connell TG; O'Donoghue DP; Sheahan K
Clin Cancer Res; 1997 Oct; 3(10):1837-40. PubMed ID: 9815571
[TBL] [Abstract][Full Text] [Related]
6. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer.
Ganesh S; Sier CF; Griffioen G; Vloedgraven HJ; de Boer A; Welvaart K; van de Velde CJ; van Krieken JH; Verheijen JH; Lamers CB
Cancer Res; 1994 Aug; 54(15):4065-71. PubMed ID: 8033138
[TBL] [Abstract][Full Text] [Related]
7. [The concentration of tissue--type plasminogen activator (t-PA) in extracts of breast cancer tissue].
Ziółkowska E; Pietrusińska E; Łozyńska-Podhrebelna D
Pol Merkur Lekarski; 2008 Dec; 25(150):489-94. PubMed ID: 19205379
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis.
Kim SJ; Shiba E; Kobayashi T; Yayoi E; Furukawa J; Takatsuka Y; Shin E; Koyama H; Inaji H; Takai S
Clin Cancer Res; 1998 Jan; 4(1):177-82. PubMed ID: 9516968
[TBL] [Abstract][Full Text] [Related]
9. Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma.
De Petro G; Tavian D; Copeta A; Portolani N; Giulini SM; Barlati S
Cancer Res; 1998 May; 58(10):2234-9. PubMed ID: 9605771
[TBL] [Abstract][Full Text] [Related]
10. Factors involved in the plasminogen activation system in human breast tumours.
Damjanovich L; Turzó C; Adány R
Thromb Haemost; 1994 Jun; 71(6):684-91. PubMed ID: 7974332
[TBL] [Abstract][Full Text] [Related]
11. The plasminogen activator system in pancreas cancer: role of t-PA in the invasive potential in vitro.
Paciucci R; Torà M; Díaz VM; Real FX
Oncogene; 1998 Feb; 16(5):625-33. PubMed ID: 9482108
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous determination of free tissue-type and free urokinase-type plasminogen activators in biological fluids by a solid-phase immunoassay.
Kuo BS; Bjornsson TD
Anal Biochem; 1993 Feb; 209(1):70-8. PubMed ID: 8465964
[TBL] [Abstract][Full Text] [Related]
13. Plasminogen activator system in oral squamous cell carcinoma.
Baker EA; Leaper DJ; Hayter JP; Dickenson AJ
Br J Oral Maxillofac Surg; 2007 Dec; 45(8):623-7. PubMed ID: 17590247
[TBL] [Abstract][Full Text] [Related]
14. Relationship of membrane-bound tissue type and urokinase type plasminogen activators in human breast cancers to estrogen and epidermal growth factor receptors.
Needham GK; Nicholson S; Angus B; Farndon JR; Harris AL
Cancer Res; 1988 Nov; 48(22):6603-7. PubMed ID: 3141047
[TBL] [Abstract][Full Text] [Related]
15. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma.
Hofmann R; Lehmer A; Buresch M; Hartung R; Ulm K
Cancer; 1996 Aug; 78(3):487-92. PubMed ID: 8697395
[TBL] [Abstract][Full Text] [Related]
16. Plasminogen activator activity in bone metastases of prostatic carcinomas as compared to primary tumors.
Kirchheimer JC; Pflüger H; Ritschl P; Hienert G; Binder BR
Invasion Metastasis; 1985; 5(6):344-55. PubMed ID: 4066206
[TBL] [Abstract][Full Text] [Related]
17. Prognostic role of urokinase-type plasminogen activator in human gliomas.
Hsu DW; Efird JT; Hedley-Whyte ET
Am J Pathol; 1995 Jul; 147(1):114-23. PubMed ID: 7604873
[TBL] [Abstract][Full Text] [Related]
18. Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps, and adenocarcinomas.
de Bruin PA; Griffioen G; Verspaget HW; Verheijen JH; Lamers CB
Cancer Res; 1987 Sep; 47(17):4654-7. PubMed ID: 3621160
[TBL] [Abstract][Full Text] [Related]
19. Plasminogen activator profiles in neoplastic tissues of the human colon.
de Bruin PA; Griffioen G; Verspaget HW; Verheijen JH; Dooijewaard G; van den Ingh HF; Lamers CB
Cancer Res; 1988 Aug; 48(16):4520-4. PubMed ID: 3260815
[TBL] [Abstract][Full Text] [Related]
20. Growth factors, tissue and urokinase-type plasminogen activators in venous ulcers.
Lagattolla NR; Stacey MC; Burnand KG; Gaffney PG
Ann Cardiol Angeiol (Paris); 1995; 44(6):299-303. PubMed ID: 7574362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]